A multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Phase 2 Multicenter, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Effectiveness of Ilofotase Alfa in Patients Susceptible to Kidney Injury After Open Heart Surgery

  • By

  • Louis Mourisse

  • Marlies Ostermann

  • Steven Thiessen

  • Alexander Dumoulin

  • Alexander P. J. Vlaar

  • Eric Hoste

  • Selim Mosbahi

  • Antoine Schneider

  • Alexander Zarbock

  • Johannes Boehm

  • Peter Rosenberger

  • Matthias Thielmann

  • Eric Dubois

  • Jonah Powell-Tuck

  • Kamran Baig

  • Wencke Renette

  • Ingrid Meex

  • Margreet Klop-Rhiel

  • Krijna Opschoor

  • Wim Vandenberghe

  • Matthias Siepe

  • Christian Strauss

  • Felix Wirth

  • Matthias Winkel

  • Liesbeth Hof

  • Maarten Kraan

  • Juliane Bernholz

  • Peter Pickkers

  • September 21, 2026

Share

Original Source(s)

Related Content